Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meet
Go back to Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meet| (NASDAQ: RCKT) | Delayed: 3.37 -0.13 (3.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.50 | 52 Week High | $ | |||
| Open | $3.47 | 52 Week Low | $ | |||
| Day High | $3.56 | P/E | N/A | |||
| Day Low | $3.35 | EPS | $ | |||
| Volume | 1,598,190 | |||||
